KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Deffered Revenue: 2017-2023

Historic Non-Current Deffered Revenue for BeOne Medicines (ONC) over the last 5 years, with Dec 2023 value amounting to $300,000.

  • BeOne Medicines' Non-Current Deffered Revenue fell 99.29% to $300,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $300,000, marking a year-over-year decrease of 99.29%. This contributed to the annual value of $300,000 for FY2023, which is 99.29% down from last year.
  • As of FY2023, BeOne Medicines' Non-Current Deffered Revenue stood at $300,000, which was down 99.29% from $42.0 million recorded in FY2022.
  • BeOne Medicines' 5-year Non-Current Deffered Revenue high stood at $220.3 million for FY2021, and its period low was $300,000 during FY2023.
  • For the 3-year period, BeOne Medicines' Non-Current Deffered Revenue averaged around $87.5 million, with its median value being $42.0 million (2022).
  • Data for BeOne Medicines' Non-Current Deffered Revenue shows a maximum YoY slumped of 99.29% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows BeOne Medicines' Non-Current Deffered Revenue stood at $220.3 million in 2021, then tumbled by 80.92% to $42.0 million in 2022, then plummeted by 99.29% to $300,000 in 2023.